NCT01059318View on ClinicalTrials.gov

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Lymphangioleiomyomatosis
Interventions
DRUG

Everolimus

Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.

Trial Locations (4)

45267

University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine,, Cincinnati

02115

Center for LAM Research and Clinical Care, Boston

Unknown

Novartis Investigative Site, Lyon

Novartis Investigative Site, Milan

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY